The market doesn't like them but you've got to admire these guys
All these intricate FDA filings and every one of them right on target.
PDUFA date Dec 20.
Form 8-K for AMARIN CORP PLC\UK
Item 8.01 Other Events
On April 23, 2013, Amarin Corporation plc (the "Company") issued a press release announcing the acceptance for review by the U.S. Food and Drug Administration ("FDA") of the Company's supplemental New Drug Application ("sNDA") which seeks approval for the marketing and sale of Vascepa(R) (icosapent ethyl) capsules for use as an adjunct to diet in the treatment of adult patients with high triglycerides (TG �200 mg/dL and